TEVA Teva Pharmaceutical Industries Ltd

Price (delayed)

$9.24

Market cap

$10.19B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.57

Enterprise value

$33.33B

Highlights
TEVA's gross margin is up by 3.5% YoY
The debt has declined by 4.1% year-on-year
Teva Pharmaceutical Industries's equity has decreased by 25% YoY but it has increased by 3.2% QoQ
TEVA's quick ratio is down by 7% YoY but it is up by 6% from the previous quarter
TEVA's revenue is down by 2.8% year-on-year

Key stats

What are the main financial stats of TEVA
Market
Shares outstanding
1.1B
Market cap
$10.19B
Enterprise value
$33.33B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.99
Price to sales (P/S)
0.62
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.04
Earnings
Revenue
$16.32B
EBIT
-$2.81B
EBITDA
-$1.35B
Free cash flow
-$176M
Per share
EPS
-$3.57
Free cash flow per share
-$0.16
Book value per share
$9.37
Revenue per share
$14.8
TBVPS
$18.73
Balance sheet
Total assets
$49.2B
Total liabilities
$37.88B
Debt
$25.58B
Equity
$10.32B
Working capital
$131M
Liquidity
Debt to equity
2.48
Current ratio
1.01
Quick ratio
0.55
Net debt/EBITDA
-17.1
Margins
EBITDA margin
-8.3%
Gross margin
46.9%
Net margin
-24%
Operating margin
-18.3%
Efficiency
Return on assets
-7.9%
Return on equity
-39.2%
Return on invested capital
-8.8%
Return on capital employed
-7.7%
Return on sales
-17.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

TEVA stock price

How has the Teva Pharmaceutical Industries stock price performed over time
Intraday
3.24%
1 week
6.33%
1 month
-1.18%
1 year
5.96%
YTD
-4.25%
QTD
-6.67%

Financial performance

How have Teva Pharmaceutical Industries's revenue and profit performed over time
Revenue
$16.32B
Gross profit
$7.65B
Operating income
-$2.99B
Net income
-$3.92B
Gross margin
46.9%
Net margin
-24%
TEVA's operating income is up by 11% from the previous quarter
The operating margin rose by 11% QoQ
TEVA's gross margin is up by 3.5% YoY
TEVA's revenue is down by 2.8% year-on-year

Growth

What is Teva Pharmaceutical Industries's growth rate over time

Valuation

What is Teva Pharmaceutical Industries stock price valuation
P/E
N/A
P/B
0.99
P/S
0.62
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.04
Teva Pharmaceutical Industries's equity has decreased by 25% YoY but it has increased by 3.2% QoQ
TEVA's price to book (P/B) is 10% lower than its last 4 quarters average of 1.1
The P/S is 23% below the 5-year quarterly average of 0.8 and 11% below the last 4 quarters average of 0.7
TEVA's revenue is down by 2.8% year-on-year

Efficiency

How efficient is Teva Pharmaceutical Industries business performance
Teva Pharmaceutical Industries's return on sales has increased by 10% QoQ
The company's return on invested capital rose by 9% QoQ
TEVA's ROE is down by 7% from the previous quarter

Dividends

What is TEVA's dividend history
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
Recent dividends

Financial health

How did Teva Pharmaceutical Industries financials performed over time
The total assets is 30% greater than the total liabilities
The total assets is down by 11% year-on-year
TEVA's quick ratio is down by 7% YoY but it is up by 6% from the previous quarter
The debt is 148% greater than the equity
TEVA's debt to equity is up by 28% YoY but it is down by 2.4% from the previous quarter
Teva Pharmaceutical Industries's equity has decreased by 25% YoY but it has increased by 3.2% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.